An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

抗体依赖性细胞介导的细胞毒性 慢性淋巴细胞白血病 癌症研究 免疫学 抗体 多发性骨髓瘤 单克隆抗体 白血病 医学
作者
Eugene A. Zhukovsky,Holly M. Horton,Matthias Peipp,Erik Pong,Matthew J. Bernett,Sher Karki,John O. Richards,Seung Y. Chu,Roland Repp,John R. Desjarlais
出处
期刊:Blood [Elsevier BV]
卷期号:112 (11): 881-881 被引量:2
标识
DOI:10.1182/blood.v112.11.881.881
摘要

Abstract CD40, a transmembrane glycoprotein belonging to the tumor necrosis factor receptor family, is an attractive target for cancers of lymphoid origin since it is expressed on most mature B-cell malignancies, some early B-cell acute lymphocytic leukemias, and multiple myeloma. Finding efficient therapies for multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and rituximab-refractory Non-Hodgkin Lymphoma (NHL) represents an unmet need. Several anti-CD40 antibodies, both agonistic and antagonistic, have demonstrated objective responses in early clinical NHL trials and thus validated this antigen as a target for lymphoproliferative diseases. Here we present the characterization of a novel Fc-engineered and humanized anti-CD40 antibody, XmAb®5485, that was generated using our XmAb antibody engineering technology. This antibody is highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells. XmAb5485 is characterized by: i) increased affinity for Fc gamma receptors (FcgR), ii) improved effector function, and iii) significantly increased antitumor potency. We investigated several direct and indirect (Fc-mediated) mechanisms of antibody-mediated cytotoxicity in vitro. The potency (EC50) of XmAb5485 in antibody-dependent cell-mediated cytotoxicity (ADCC) increased up to 150-fold relative to the native non Fc-engineered version (anti-CD40 IgG1) of the antibody in a screen of Burkitt’s lymphoma [BL], CLL and MM-derived cell lines. In the same cell lines, ADCC potency and maximal efficacy (% lysis) of XmAb5485 were also superior to that of rituximab: 74- and 1.3-fold higher in CLL, 12.5- and 1.4-fold higher in BL, and 190- and 1.9-fold higher in MM. In a MM cell line with low density of CD40 expression (~3500 per cell) XmAb5485 facilitated efficient ADCC whereas anti-CD40 IgG1 was virtually ineffective. Furthermore, using a BL cell line (Ramos) XmAb5485 displayed antibody-dependent cellular phagocytosis (ADCP) with potency and efficacy increased relative to rituximab (15- and 1.6-fold) and anti-CD40 IgG1 (5- and 1.2-fold). XmAb5485 also exhibited anti-proliferative apoptotic activity that was similar to that of rituximab. Ex vivo, XmAb5485 mediated potent ADCC of multiple primary patient-derived CLL, MCL, and plasma cell leukemia (PCL, an aggressive form of MM) cells, with substantially increased potency and efficacy relative to rituximab; in contrast, anti-CD40 IgG1 displayed minimal or no activity in these primary tumor cells. In vivo, in an established large (210–350 mm3) sc Ramos tumor xenograft model, 6 mg/kg XmAb5485 cured 80% of mice of detectable tumors and displayed statistically significant superiority over anti-CD40 IgG1. In contrast, only 7% of animals in the rituximab cohort were cured. In summary, our data suggest that XmAb5485, an anti-CD40 Fc variant antibody engineered for increased effector function, is a promising next-generation immunotherapeutic for leukemias, lymphomas, and multiple myeloma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
有魅力访曼完成签到,获得积分10
4秒前
仁爱的沁发布了新的文献求助10
5秒前
5秒前
爱科研的七七完成签到,获得积分10
6秒前
6秒前
大富婆发布了新的文献求助10
8秒前
123的应助被鸡你太美采纳,获得10
8秒前
简单晓博发布了新的文献求助10
8秒前
8秒前
烟花的应助被风吹麦浪采纳,获得10
9秒前
Owen的应助被风吹麦浪采纳,获得10
9秒前
慕青的应助被风吹麦浪采纳,获得10
9秒前
10秒前
软软垂耳兔完成签到,获得积分10
10秒前
11秒前
张琪培发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
Saturn完成签到,获得积分10
12秒前
周周发布了新的文献求助10
14秒前
负责月光发布了新的文献求助20
15秒前
阿九完成签到 ,获得积分10
15秒前
阿蕊发布了新的文献求助10
15秒前
15秒前
16秒前
梦白完成签到 ,获得积分10
16秒前
Clover04的应助被仁爱的沁采纳,获得150
16秒前
17秒前
乌乌发布了新的文献求助10
19秒前
123的应助被牧百川采纳,获得10
21秒前
lql完成签到,获得积分10
22秒前
我是老大的应助被默默的含蕾采纳,获得10
23秒前
24秒前
无限糜完成签到 ,获得积分10
24秒前
万能图书馆的应助被啦啦啦采纳,获得10
25秒前
hzc完成签到,获得积分10
25秒前
华仔的应助被周周采纳,获得10
25秒前
banana发布了新的文献求助100
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183381
求助须知:如何正确求助?哪些是违规求助? 9572627
关于积分的说明 21826833
捐赠科研通 7780405
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558177
邀请新用户注册赠送积分活动 2480309